RARS1 and hepatocellular carcinoma: Although not statistically significant, we found that loss of 4q13.3-q35.2, 13q12.1-q21.2, as well as gain of 7q11.2-q35 was observed with a higher frequency in the HBV(+)/AFB1(+), HBV(+)/AFB1(-) and HBV(-)/AFB1(+) groups compared to the HBV(-)/AFB(-) group, suggesting that genes covered by these 3 RARs may play a role in HBV- and/or AFB1-related HCC carcinogenesis.